On 3/30/2017, Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) closed at $3.05 in last trading day. After noting the initial trading entry at $3.20, it reached to a day’s high of $3.25 and moved to a day’s low of $2.95. The recent daily volume was 544.41 thousand as contrast to it’s an average volume of 287 thousand.
The last close of the AEterna Zentaris Inc. stock reflects that it traded up +0.28% from its 50-day moving average of $3.04. The stock traded below -8.97% to its 200-day MA of $3.35. Furthermore, it moved lower -45.44% from its 52-week high of $5.59 and +29.79% up from $2.35, which is 52-week low of the stock.
Aeterna Zentaris Inc.’s (AEZS) moved with shift of 10.91% in the past week. Over the last three months, the shares of the company have changed -14.08% and performed -11.59% over the last six months. The stock currently has Monthly Volatility of 6.41% and Weekly Volatility of 6.90%.
March 30, 2017 Aeterna Zentaris Inc. announced that, following its meeting with the U.S. Food and Drug Administration (the “FDA” or the “Agency”) on March 29, 2017, the Company intends to file a new drug application (“NDA”) seeking approval of Macrilen™ (macimorelin) for the evaluation of growth hormone deficiency in adults (“AGHD”).
Commenting on the meeting, Dr. Richard Sachse, the Company’s Chief Scientific Officer, stated, “During our meeting with the FDA, the Agency stated that the clinical studies we performed with respect to Macrilen™ address the prior deficiencies mentioned in the November 2014 complete response letter. This conclusion paves the way for our re-submission of an NDA for Macrilen™, which we expect to file in the third quarter of this year. While indicating that our conclusions regarding the performance of Macrilen™ are review issues subject to an examination of the complete data set, the Agency indicated that the summary data we submitted prior to the meeting appear to support the propositions we advanced. Most importantly, the FDA specified the additional statistical analysis of existing data that would be required to further support our conclusions. We expect that we can provide those data in a compelling fashion and demonstrate that Macrilen™ is a robust, repeatable test, demonstrating adequate sensitivity and specificity and that the performance of the product would be improved by utilizing a more appropriate cut-off point.”
Clorox Company (NYSE:CLX) finalized the last transaction at value of $135.29, with a daily change of -0.49% or -0.67 points. The company maintained volume of 520.03 thousand shares. In past trading day, the stock hit the maximum price of $136.03 and touched to minimum value of $135.20. It has a market cap of $ 17.35B.
As of last trade close, the stock is trading downside -3.69% from its one year high of $140.47 and moved +21.62% upward from $111.24, which is one year low of the stock.
The stock traded below -0.05% from its 50-day moving average of $135.36. Furthermore, the stock moved up +9.38% to its 200-day MA of $ 123.68.
During the last month, The Clorox Company’s (CLX) has changed -1.36% and performed 8.79% over the last 6 months. The mean rating score for this stock is at 2.90. This rating scale contains from 1 to 5 with 5 representing a Strong Sell, 1 signifying a Strong Buy and 3 demonstrating a Hold. The Volatility was noted at 0.82% in recent month and observed Weekly Volatility of 0.81%.
March 27, 2017 Clorox Professional Products Company announced the Clorox® Total 360™ System, an innovative new surface treatment system that combines proven electrostatic technology with trusted Clorox® products to quickly and easily provide superior coverage in even the hardest-to-reach places. Using patented electrostatic technology to optimize product delivery, the Clorox® Total 360™ System is a cost-effective solution for efficient, comprehensive surface treatment that is designed to help keep facilities healthier while saving them time, money and labor.